The Medicaid population has significantly higher hepatitis C virus (HCV) prevalence and mortality rates than patients with private insurance. These data must be considered when policy makers assess providing additional support to Medicaid programs for HCV elimination.
Objectives: To assess the association of payer status and mortality in hepatitis C virus (HCV)—infected patients.
Study Design: For this retrospective observational study, we used the National Health and Nutrition Examination Survey from 2000 to 2010. Adults with complete data on medical questionnaires, HCV RNA, insurance types, and mortality follow-ups were included.
Methods: We used Cox proportional hazards models to evaluate independent associations of insurance type with mortality in HCV-infected individuals. These models were rerun in the subset of HCV-positive subjects to determine the association of insurance type with mortality. The data used in this study predated the implementation of the Affordable Care Act.
Results: Among 19,452 eligible participants, 311 (1.4%) were HCV positive. HCV-positive patients were older, were more likely to be non-Hispanic black and male, and had higher prevalence of hypertension (all P <.001). HCV-positive patients were also less likely to have private insurance and more likely to be covered by Medicaid or be uninsured relative to HCV-negative patients (P <.001). Among HCV-positive patients, after adjustment for confounders, those with Medicaid coverage had an increased risk of mortality compared with those with private insurance (hazard ratio [HR], 6.31; 95% CI, 1.22-29.94) and uninsured individuals (HR, 8.83; 95% CI, 1.56-49.99).
Conclusions: Patients who have HCV are more likely to be uninsured or covered by Medicaid. HCV-positive patients with Medicaid have an increased mortality risk compared with those with private insurance. Given the high burden of HCV infection and adverse prognosis among individuals covered by Medicaid, policy makers must prioritize funding and supporting Medicaid programs.
Am J Manag Care. 2019;25(2):61-67Takeaway Points
In the United States, the estimated prevalence of individuals with hepatitis C virus (HCV) ranges from 5.2 million to 7.1 million.1-3 The majority of individuals infected with HCV were born between 1945 and 1964—the generation known as baby boomers—but there has been an increase in the number of infected individuals younger than 30 years due to intravenous drug use, which has contributed to a bimodal age distribution of HCV burden.4-6 If untreated, HCV can cause significant liver disease, making it the leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation in the United States.7-10 Until recently, the standard treatment for HCV was interferon based and had low sustained virologic response (SVR) rates, resulted in frequent adverse effects, and impaired patients’ health-related quality of life.11-13 However, new treatment regimens containing direct-acting antivirals (DAAs) boast cure rates higher than 96% and improve health-related quality of life during treatment and post SVR.14-17 Although the effectiveness of HCV treatment has steadily improved, these regimens have remained relatively expensive, with potential budgetary implications for payers.18 This issue is especially important to the Medicare and Medicaid programs because of the high burden of HCV infection in their covered populations.19,20 In fact, Medicare and Medicaid are currently the primary payers for the majority of HCV-associated cirrhosis hospitalizations.21 With the aging of the baby boomers with HCV and the high prevalence of HCV in the Medicare and Medicaid populations, the future ability of these programs to cover the cost of the new and more costly anti-HCV treatments can be challenging.
It is important to note that in the United States, the affordability of healthcare, especially medications, is largely dependent on insurance type. Some types of insurance cover nearly all the up-front costs of medications, whereas others require individuals to pay large sums of money for out-of-pocket expenditures. In this context, it is possible that insurance type may influence health outcomes by creating potential barriers to accessing beneficial treatment.19-22 This is especially relevant for the new anti-HCV regimens that have high efficacy but also substantial budgetary impact.17 In fact, these up-front costs of covering the new anti-HCV medications have led to substantial access restrictions by some payers, especially some states’ Medicaid programs.23 In this context, it is possible that the characteristics of patients with HCV covered by different types of insurance, coupled with their ease of access to treatment regimens, could potentially affect their outcomes. Therefore, the aim of our analysis was to use National Health and Nutrition Examination Survey (NHANES) data and linked mortality files to assess the burden and outcomes of HCV infection according to insurance coverage types in the United States.
MATERIALS AND METHODS
NHANES is a stratified, multistage probability sample representative of the noninstitutionalized civilian US population. The third NHANES was conducted in 1988-1994; beginning in 1999, the survey became a continuous program, with every 2 years representing 1 cycle. Each survey is composed of a home interview for demographic, socioeconomic, dietary, and health-related questions; a subsequent standardized physical examination; and laboratory tests from blood samples collected at a mobile examination center. Detailed descriptions of the plan and operation of each survey are available elsewhere.24 We used data from 5 NHANES cycles (2001-2010). To determine NHANES participants’ mortality status, we used the public-use Linked Mortality File, in which participants who were 18 years and older are linked to death records from the National Death Index through December 31, 2011.25 The eAppendix Figure (eAppendix available at ajmc.com) represents the inclusion and exclusion criteria for the study population.
Collected Data and Definitions
Eligible participants were considered to have chronic hepatitis C (defined as HCV positive) if their serum tested positive for HCV RNA. Participants without HCV RNA were defined as HCV negative. Insurance types were categorized into 4 groups: (1) private insurance, including any military/state/government insurance; (2) Medicare; (3) Medicaid; and (4) uninsured. Patients with dual insurance (eg, private insurance and Medicare, Medicaid and Medicare) who could not be classified into a payer category were excluded. The following comorbidities were ascertained largely through the questionnaires completed by NHANES participants: history of arthritis, cancer, chronic obstructive pulmonary disease (COPD, which included either chronic bronchitis or emphysema), congestive heart disease (CHD), ischemic heart disease (IHD), kidney failure, and stroke.
Other clinical variables were defined as follows. Obesity was defined as a body mass index of 30 kg/m2 or greater, and type 2 diabetes (T2D) was defined as a fasting glucose value of 126 mg/dL or greater or current use of oral hypoglycemic and/or insulin. A diagnosis of hypertension (HTN) required a mean systolic blood pressure of 140 mm Hg or greater, mean diastolic blood pressure of 90 mm Hg or greater, or current use of an antihypertensive. Hypercholesterolemia was defined as a total serum cholesterol of 200 mg/dL or greater, a low-density lipoprotein of 130 mg/dL or greater, current use of an antihyperlipidemic drug, or a high-density lipoprotein (HDL) of 40 mg/dL or less in men or 50 mg/dL or less in women. A diagnosis of metabolic syndrome was defined as having at least 3 of the following26: waist circumference greater than 102 cm in men or 88 cm in women, fasting plasma glucose greater than 110 mg/dL, blood pressure greater than 130/85 mm Hg, elevated triglycerides greater than 150 mg/dL, and HDL of 40 mg/dL or less in men or 50 mg/dL or less in women.
Participants’ age, race/ethnicity, sex, military service, college degree, marital status, employment, excessive alcohol consumption (if more than 20 g per day in men and more than 10 g per day in women), smoking status, and poverty income ratio (PIR) were based on self-reported data from the NHANES in-home interview.
Of note, the data used in this study predated the implementation of the Affordable Care Act (ACA).
Sampling weights provided by the National Center for Health Statistics (NCHS) were used to account for survey nonresponse and sampling strategy. For national representation, original weights in our merged sample were modified using the method recommended by NCHS.25 Sampling errors were estimated by the Taylor linearization method using subpopulation (domain) analysis. Variables were expressed as weighted means or weighted percentages (standard errors). Differences between groups were evaluated using a t statistic for continuous variables and the Rao-Scott χ2 test for categorical variables. Age adjustment estimates were calculated by the direct method to the standard 2000 United States population estimates using the age groups of 18 to 44 years, 45 to 54 years, 55 to 64 years, and 65 years or older.
Among HCV-positive individuals, weighted all-cause mortality rates were stratified by types of insurance. The Cox models were implemented in the HCV-positive subjects to determine the association of insurance type with all-cause mortality adjusting for important covariates. We used 2 models: Model 1 adjusted for sociodemographics including age, gender, race, PIR, education, and marital status, and model 2 adjusted for the sociodemographic and clinical variables selected by bidirectional stepwise regression. The proportional hazards assumptions of the Cox models were examined by testing time-dependent covariates.27 All analyses were performed with SAS software, version 9.4 (SAS Institute; Cary, North Carolina).
Characteristics of Study Population
After applying exclusion criteria, 19,452 individuals from 5 NHANES cycles (2001-2010) were considered eligible for this study (eAppendix Figure). Mean age was 43.3 years, 48% were male, and 69.5% were non-Hispanic white, 11.2% were non-Hispanic black, 13.6% were Hispanic, and 5.8% were of other racial background (Table 1). Of the 19,452, 311 individuals (weighted prevalence of HCV, 1.37%; 95% CI, 1.15%-1.59%) had detectable HCV RNA. In terms of comorbidities, 33.2% were obese, 7.4% had T2D, 68.5% had hypercholesterolemia, 30.4% had HTN, and 16.6% had metabolic syndrome (Table 1). Additionally, 68.3% had private insurance, 5.8% had Medicare, 4.3% had Medicaid, and 21.7% had no insurance (Table 2). The age-adjusted prevalence of HCV was highest among individuals with Medicaid (2.58%), followed by the uninsured (2.17%), those with Medicare (1.24%), and those with private insurance (0.81%) (Figure and eAppendix Table 1).
Comparison of HCV-Positive Cohort With the HCV-Negative Controls
The results of the comparison between the HCV-positive cohort and HCV-negative controls are summarized in Table 1. The mean age of HCV-positive subjects was 48.1 years, 64.6% were non-Hispanic white, and 65.7% were male. As expected, relative to HCV-negative subjects, those with HCV were older and more likely to be male, non-Hispanic black, and unmarried. HCV-positive patients were less likely to be employed and had lower income (all P <.05). Additionally, HCV-positive participants had significantly higher prevalence of HTN and of history of arthritis, COPD, congestive heart disease, kidney failure, and stroke (P <.05) (Table 1). Compared with HCV-negative controls, HCV-positive subjects were more likely to be covered by Medicaid or be uninsured and less likely to have private insurance (Table 2).
Comparison of HCV-Positive Cohort Across Insurance Types
There were significant differences in sociodemographics and comorbid conditions according to type of insurance. Compared with HCV-positive patients with private insurance, those with Medicare or Medicaid insurance were less likely to be non-Hispanic white and more likely to be non-Hispanic black, be unmarried, and have lower income (P <.05 for each comparison) (Table 3).
As expected, HCV-positive patients with Medicare were older, more likely to be non-Hispanic black, and more likely to have comorbidities such as HTN and T2D, as well as history of arthritis, cancer, CHD, IHD, kidney failure, and stroke, compared with those with private insurance or the uninsured.
Also, HCV-positive patients with Medicaid had higher rates of obesity (41.9% vs 20.1% among Medicare and 12.0% among uninsured), T2D (27.4% vs 10.0% among private and 6.7% among uninsured), HTN (52.9% vs 34.6% among uninsured), metabolic syndrome (32.9% vs 14.9% among private and 6.6% among uninsured), arthritis (46.4% vs 27.0% among private), CHD (7.4% vs 3.8% among private and 1.9% among uninsured), and IHD (8.0% vs 1.6% among private) (Table 3).
Compared with other patients, HCV-positive patients with private insurance were more likely to have high income and to be non-Hispanic white, married, and employed.
Finally, the uninsured HCV-positive patients were younger, had lower income, and had lower rates of comorbid conditions compared with the insured HCV-positive patients (data not shown).
All-Cause Mortality Among HCV-Positive Cohort Across Insurance Types
In this subgroup analysis, only participants with HCV (n = 311) were included. Through the follow-up period (median, 58 months), there were significant differences in all-cause mortality rates across insurance types. Weighted unadjusted all-cause mortality was the highest among patients with Medicare (45.4%), followed by Medicaid (23.7%), private (7.9%), and uninsured (6.8%) (Table 4). However, after adjusting for sociodemographic variables, HCV-positive patients with Medicaid had significantly higher all-cause mortality compared with HCV-positive patients with private insurance (hazard ratio [HR], 5.81; 95% CI, 1.15-29.29) and the uninsured (HR, 5.01; 95% CI, 1.19-21.01). In fact, even after adjustments by stepwise selection, the model still indicated that those with Medicaid had an increased risk of mortality compared with those with private insurance (HR, 6.31; 95% CI, 1.22-29.94) and the uninsured (HR, 8.83; 95% CI, 1.56-49.99) (Table 4).
Our study reveals that among the NHANES population, the prevalence of HCV is quite high among individuals who are covered by Medicare and Medicaid and among the uninsured population.
Additionally, our analysis showed that presence of HCV infection is an independent risk factor for mortality (eAppendix Table 2) and that the risk further increases in the subgroup of HCV-infected individuals who are covered by Medicare or Medicaid—specifically, those covered by Medicaid (Table 4). To our knowledge, this is the first study to document an association between mortality and Medicaid coverage in HCV-infected subjects using a population-based database.
When assessing the mortality of patients enrolled in this NHANES-based analysis, we also confirmed some of the other well-known risk factors for mortality. Those factors include HCV status, age, smoking status, comorbidities, and some sociodemographic components, such as income level (eAppendix Table 2). These findings have also been reported in previous studies and are reflected in our results supporting the validity of our analyses.28-32 Specifically, our data analysis shows that HCV infection is an independent risk factor for mortality, as HCV-infected individuals are nearly twice as likely to experience mortality as HCV-negative individuals. Numerous studies have examined and confirmed this increased risk of mortality in HCV-positive subjects.33-35 A CDC report highlights that the HCV deaths in the United States have now surpassed deaths from 60 other infectious conditions combined.35 Furthermore, El-Kamary et al demonstrated that HCV all-cause mortality is more than twice that of HCV-negative individuals, indicating that HCV-positive individuals are at a higher risk of death even after accounting for liver-related morbidity.33 Also, Sayiner et al concluded that among Medicare recipients, a diagnosis of HCV is independently associated with higher mortality.34
Additionally, our study found that among the entire study population, those with Medicaid had an increased risk of all-cause mortality. This was confirmed after adjustment for confounders. Several other studies have reported an association between insurance type and negative health outcomes.36-41 Saunders et al examined a nationally representative sample of individuals with albuminuria and concluded that lack of insurance and having public insurance such as Medicaid were both associated with increased mortality compared with private insurance, even after controlling for numerous variables.36 Furthermore, a nationally representative study of Americans hospitalized for myocardial infarction, stroke, or pneumonia found significantly lower in-hospital mortality for privately insured patients relative to the uninsured or to Medicaid recipients.38 Similarly, multiple studies assessing cancer survival and insurance status concluded that the uninsured and those with Medicaid experienced shorter survival relative to those with all other types of insurance.39-45
The exact reasons for this increased mortality in HCV-positive patients with Medicaid are not known but could potentially be related to other confounders that are not captured by these databases. These factors could include health literacy about HCV, access to preventive services, access to specialized care for HCV, number of HCV treatment providers who accept Medicaid patients, and other barriers to screening for HCV and linkage to appropriate care.
Regardless of the reasons for the adverse outcomes, our analysis provides evidence to support the conundrum faced by many Medicaid recipients and Medicaid programs in the United States. These programs cover populations that not only have high prevalence of HCV but also are at increased risk for mortality. In fact, our data show that HCV-infected individuals with Medicaid were nearly 10 times more likely to experience mortality compared with HCV-infected individuals who are covered by private insurance, and this risk was independent of a large number of confounders. The fiscal and ethical challenges of facing the combination of high prevalence and high mortality of HCV are a double-edged sword for Medicaid programs. In this context, it is important that Medicaid programs are funded appropriately to deal with this ongoing major challenge.
It is important to note that our study examined data only up to 2010, the same year the ACA was signed into law. This major reform changed the healthcare landscape in the United States, in particular by increasing the number of Americans covered by Medicaid.46 This is especially important because our data show the highest prevalence of HCV in the uninsured. As these individuals are increasingly being covered through Medicaid expansion, the burden of HCV to Medicaid will certainly increase. Also, after 2011, treatment for HCV improved dramatically with the development of DAAs.47,48 Consequently, a record number of people could become candidates for these highly effective HCV treatment options with minimal adverse events.14 Despite this high efficacy, there is evidence that Medicaid programs are not able to cope with anti-HCV treatment coverage and some programs have created substantial barriers to treatment.17,23,49 Given the time frame of our study, we are not able to assess the impact of Medicaid expansion or new antiviral regimens on the mortality of patients with HCV covered by Medicaid. Nevertheless, the increasing number of HCV-infected individuals covered through Medicaid expansion and restrictions in providing treatment regimens could have exacerbated the problem. In this context, it is important that future studies assess outcomes in the Medicaid population after these recent changes.
Our study has several limitations. NHANES collects insurance type at the time of interview without any validation. If types of insurance were misclassified, it might dilute the true effect on mortality in our sample. This is important because the reported prevalence of Medicaid and Medicare recipients in our study is smaller than in the general population for the study period.50 After the interview, the gain or loss of coverage was not measurable. Furthermore, NHANES does not have data regarding the duration of insurance coverage or the amount of cost sharing (out-of-pocket expenses) experienced by the participants. Also, this analysis included a time period that predates ACA legislation in the United States. The impact of the insurance expansion through ACA must be analyzed in the future. Lastly, we excluded dually eligible individuals from our study because they were classified as having 2 types of insurance. We believe this exclusion had a minimal effect because this cohort included fewer than 1% of NHANES participants from 2000 to 2010. Nevertheless, our analysis still produced a number of results that are supported by the literature, indicating the validity of our analytic approach.
Our data show that HCV-infected individuals are at twice the risk for mortality. Additionally, patients with Medicaid had higher mortality than privately insured patients with HCV. In fact, having Medicaid coverage in HCV-infected patients independently contributed to the mortality outcomes. Given the high prevalence of HCV in the Medicaid population and their increased risk of mortality (both related to HCV and Medicaid coverage), these patients require special attention. Now that the availability of highly effective treatment regimens is wider, access to these regimens for the Medicaid population with HCV is urgently needed. In this context, it is critical that policy makers provide adequate resources to Medicaid programs to deal with this urgent need. Further research is warranted to assess the impact of the ACA, new antiviral regimens, and recent changes in the payer coverage restrictions for HCV treatment on the coverage and completion of treatment among these HCV-infected patients.Author Affiliations: Betty and Guy Beatty Center for Integrated Research, Inova Health System (HB, JP, PG, LdA, CE, ZMY), Falls Church, VA; Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital (ZMY), Falls Church, VA.
Source of Funding: None.
Author Disclosures: Dr Younossi reports consultancies or paid advisory boards for Gilead, Intercept, and Bristol-Myers Squibb. The remaining authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (HB, JP, PG, CE, ZMY); acquisition of data (JP, ZMY); analysis and interpretation of data (HB, JP, PG, CE, ZMY); drafting of the manuscript (HB, JP, PG, LdA, CE, ZMY); critical revision of the manuscript for important intellectual content (HB, PG, LdA, CE, ZMY); statistical analysis (JP); obtaining funding (ZMY); administrative, technical, or logistic support (LdA); and supervision (ZMY).
Address Correspondence to: Zobair M. Younossi, MD, MPH, Betty and Guy Beatty Center for Integrated Research, Inova Health System, Claude Moore Health Education and Research Building, 3300 Gallows Rd, Falls Church, VA 22042. Email: Zobair.Younossi@inova.org.REFERENCES
1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090-1101. doi: 10.1111/j.1478-3231.2011.02494.x.
2. Golabi P, Otgonsuren M, Suen W, Koenig AB, Noor B, Younossi ZM. Predictors of inpatient mortality and resource utilization for the elderly patients with chronic hepatitis C (CH-C) in the United States. Medicine (Baltimore). 2016;95(3):e2482. doi: 10.1097/MD.0000000000002482.
3. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39(5):518-531. doi: 10.1111/apt.12625.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714. doi: 10.7326/0003-4819-144-10-200605160-00004.
5. Page K, Hahn JA, Evans J, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200(8):1216-1226. doi: 10.1086/605947.
6. Viral hepatitis surveillance: United States, 2015. CDC website. cdc.gov/hepatitis/statistics/2015surveillance/pdfs/2015HepSurveillanceRpt.pdf. Updated June 19, 2017. Accessed February 28, 2018.
7. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745-750. doi: 10.1056/NEJM199903113401001.
8. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362(9401):2095-2100. doi: 10.1016/S0140-6736(03)15109-4.
9. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436-2441. doi: 10.3748/wjg.v13.i17.2436.
10. Younossi ZM, Stepanova M, Saab S, et al. The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. J Viral Hepat. 2016;23(1):53-61. doi: 10.1111/jvh.12449.
11. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61(6):1798-1808. doi: 10.1002/hep.27724.
12. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient’s journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42(3):286-295. doi: 10.1111/apt.13269.
13. Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore). 2016;95(28):e4151. doi: 10.1097/MD.0000000000004151.
14. Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354-369. doi: 10.1056/NEJMoa1702417.
15. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483-1493. doi: 10.1056/NEJMoa1316366.
16. Stepanova M, Younossi ZM. Interferon-free regimens for chronic hepatitis C: barriers due to treatment candidacy and insurance coverage. Dig Dis Sci. 2015;60(11):3248-3251. doi: 10.1007/s10620-015-3709-6.
17. Lin M, Kramer J, White D, et al. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017;46(10):992-1000. doi: 10.1111/apt.14328.
18. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;46(suppl 5):S186-S196. doi: 10.1016/j.dld.2014.09.025.
19. Institute of Medicine. Care Without Coverage: Too Little, Too Late. Washington, DC: National Academies Press; 2014.
20. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011;53(3):737-745. doi: 10.1002/hep.24131.
21. Wong RJ, Farzinkhou S, Tana MM, Castaneda G, Liu B, Bhuket T. Cirrhosis related hospitalizations are mostly due to chronic hepatitis C virus and largely paid for by Medicare and Medicaid: an analysis of 2007-2013 nationwide inpatient sample data. Hepatology. 2017;66(suppl 1):411A. Abstract 767. doi: 10.1002/hep.29501.
22. Stepanova M, Younossi ZM. Economic burden of hepatitis C infection. Clin Liver Dis. 2017;21(3):579-594. doi: 10.1016/j.cld.2017.03.012.
23. Wong RJ, Jain MK, Therapondos G, et al. Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. Am J Gastroenterol. 2018;113(9):1329-1338. doi: 10.1038/s41395-018-0033-8.
24. Johnson CL, Paulose-Ram R, Ogden CL, et al. National Health and Nutrition Examination Survey: Analytic Guidelines, 1999-2010. Washington, DC: National Center for Health Statistics; 2013. cdc.gov/nchs/data/series/sr_02/sr02_161.pdf. Accessed February 20, 2018.
25. 2011 Public-use Linked Mortality Files. CDC website. cdc.gov/nchs/data-linkage/mortality-public.htm. Updated November 21, 2017. Accessed December 2, 2018.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. doi: 10.1001/jama.285.19.2486.
27. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Institute; 1995.
28. Kennedy BP, Kawachi I, Glass R, Prothrow-Stith D. Income distribution, socioeconomic status, and self rated health in the United States: multilevel analysis. BMJ. 1998;317(7163):917-921. doi: 10.1136/bmj.317.7163.917.
29. Idler EL, Angel RJ. Self-rated health and mortality in the NHANES-I Epidemiologic Follow-up Study. Am J Public Health. 1990;80(4):446-452.
30. Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality—beyond established causes. N Engl J Med. 2015;372(7):631-640. doi: 10.1056/NEJMsa1407211.
31. Younossi ZM, Otgonsuren M, Henry L, et al. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. J Viral Hepat. 2015;22(2):137-145. doi: 10.1111/jvh.12262.
32. Younossi ZM, Stepanova M. Hepatitis C virus infection, age, and Hispanic ethnicity increase mortality from liver cancer in the United States. Clin Gastroenterol Hepatol. 2010;8(8):718-723. doi: 10.1016/j.cgh.2010.04.017.
33. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis. 2011;53(2):150-157. doi: 10.1093/cid/cir306.
34. Sayiner M, Wymer M, Golabi P, Ford J, Srishord I, Younossi ZM. Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. Aliment Pharmacol Ther. 2016;43(10):1060-1068. doi: 10.1111/apt.13592.
35. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287-1288. doi: 10.1093/cid/ciw111.
36. Saunders MR, Ricardo AC, Chen J, Chin MH, Lash JP. Association between insurance status and mortality in individuals with albuminuria: an observational cohort study. BMC Nephrol. 2016;17:27. doi: 10.1186/s12882-016-0239-1.
37. LaPar DJ, Bhamidipati CM, Mery CM, et al. Primary payer status affects mortality for major surgical operations. Ann Surg. 2010;252(3):544-550; discussion 550-551. doi: 10.1097/SLA.0b013e3181e8fd75.
38. Hasan O, Orav EJ, Hicks LS. Insurance status and hospital care for myocardial infarction, stroke, and pneumonia. J Hosp Med. 2010;5(8):452-459. doi: 10.1002/jhm.687.
39. Rong X, Yang W, Garzon-Muvdi T, et al. Influence of insurance status on survival of adults with glioblastoma multiforme: a population-based study. Cancer. 2016;122(20):3157-3165. doi: 10.1002/cncr.30160.
40. McDavid K, Tucker TC, Sloggett A, Coleman MP. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med. 2003;163(18):2135-2144. doi: 10.1001/archinte.163.18.2135.
41. Zhang JX, Huang ES, Drum ML, et al. Insurance status and quality of diabetes care in community health centers. Am J Public Health. 2009;99(4):742-747. doi: 10.2105/AJPH.2007.125534.
42. Pulte D, Jansen L, Brenner H. Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma. Oncologist. 2015;20(5):554-561. doi: 10.1634/theoncologist.2014-0386.
43. Gerry JM, Weiser TG, Spain DA, Staudenmayer KL. Uninsured status may be more predictive of outcomes among the severely injured than minority race. Injury. 2016;47(1):197-202. doi: 10.1016/j.injury.2015.09.003.
44. Ong JP, Collantes R, Pitts A, Martin L, Sheridan M, Younossi ZM. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol. 2005;39(9):826-830. doi: 10.1097/01.mcg.0000177258.95562.43.
45. Bittoni MA, Wexler R, Spees CK, Clinton SK, Taylor CA. Lack of private health insurance is associated with higher mortality from cancer and other chronic diseases, poor diet quality, and inflammatory biomarkers in the United States. Prev Med. 2015;81:420-426. doi: 10.1016/j.ypmed.2015.09.016.
46. Patient Protection and Affordable Care Act, HR 3590, 111th Cong, 2nd Sess (2010).
47. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015;8(5):298-312. doi: 10.1177/1756283X15587481.
48. Younossi Z, Blissett D, Blissett R, et al. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver Int. 2018;38(2):258-265. doi: 10.1111/liv.13519.
49. Holahan J, Buettgens M, Carroll C, Dorn S. The cost and coverage implications of the ACA Medicaid expansion: national and state-by-state analysis. Kaiser Family Foundation website. kff.org/health-reform/report/the-cost-and-coverage-implications-of-the. Published November 1, 2012. Accessed January 10, 2017.
50. Table HIA-4: health insurance coverage status and type of coverage by state all people: 1999 to 2009. United States Census Bureau website. census.gov/data/tables/time-series/demo/health-insurance/historical-series/hia.html. Published September 5, 2017. Accessed January 9, 2018.